Lisocabtagene maraleucel shows superior 3-year outcomes over standard care in second-line large B-cell lymphoma.
Lisocabtagene maraleucel demonstrated superior efficacy, with a median event-free survival of 29.5 months compared to 2.4 months for standard of care in second-line large B-cell lymphoma . The 36-month overall survival rate reached 63% for lisocabtagene maraleucel vs 52% for standard care, with progression-free survival rates of 51% vs 26.
5%, respectively.A total of 184 adults eligible for autologous stem cell transplantation were randomly assigned 1:1 to receive either lisocabtagene maraleucel or standard of care.chimeric antigen receptor-positive T cells, while the standard-of-care arm received three cycles of protocol-defined immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation. Bridging therapy was permitted at investigator discretion for disease control during lisocabtagene maraleucel manufacturing. The study was conducted following Declaration of Helsinki guidelines, International Conference on Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements.Median event-free survival was 29.5 months for lisocabtagene maraleucel vs 2.4 months for standard of care . Median progression-free survival was not reached for lisocabtagene maraleucel vs 6.2 months for standard of care, with 36-month rates of 51% vs 26.5%.At 3-year follow-up, lisocabtagene maraleucel demonstrated superior, more durable efficacy vs standard of care with a favorable safety profile and no new safety signals.“These results provide long-term evidence to support liso-cel as an effective second-line treatment with curative potential for patients with primary refractory/early relapsed LBCL,” the authors of the study wrote.When interpreting overall survival data, the crossover design of the study needs to be considered. Additionally, the study was not powered to evaluate statistical differences in overall survival between treatment arms due to limited number of events in both groups.The study was supported by Celgene, a Bristol Myers Squibb Company. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
Biologics Non-Hodgkin' S Lymphoma Non-Hodgkin Lymphoma NHL Non-Hodgkin Lymphoma (NHL) B-Cell Lymphoma Lymphoma Malignant Lymphoma Stem Cell Research &Amp Therapy Stem Cell Transplantation Stem Cell Therapy Stem Cell Research And Therapy Transplantation Of Stem Cells Stem Cell Chimeric Antigen Receptor T-Cell Therapy Chimeric Antigen Receptors Chimeric Immunoreceptors
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
DLBCL: FDA Rejects BLA for Second-Line Glofitamab ComboAmong reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing glofitamab as a second-line treatment for DLBCL.
Read more »
Inman: Instant analysis as Purdy excels in 49ers camp’s second practiceHere are the highs and lows from the 49ers’ second practice of training camp Thursday.
Read more »
Cadillac is finally set to return to the UK with two-car line-upGM returns to UK with Cadillac's premium electric SUVs, and other brands could follow
Read more »
Browns D-Line vs. Eagles O-Line: How they fared on Day 1 of joint practiceObservations from Browns vs. Eagles joint practice on Wednesday.
Read more »
Utahns line streets for procession of Tremonton officers killed in line of dutyAfter 3 decades spent in the sunny (and humid) South Florida media world, Jeff has traveled to across the country to partake in the delights of The Beehive State.
Read more »
Intense video shows massive explosion rock Wilmington, North Carolina, after car hits building gas lineToday's Video Headlines: 08/19/25
Read more »